{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-147030","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2024-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.347371+00:00","generated_at":"2026-06-01T08:39:19.942206+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Kura Oncology completes enrollment of 85 patients in Phase 2 KOMET-001 trial; topline data expected early 2025","bullets":["Final enrollment of 85 patients in Phase 2 registration-directed trial of menin inhibitor ziftomenib for NPM1-mutant AML.","Topline data from KOMET-001 trial expected in early 2025.","Trial targets relapsed/refractory NPM1-mutant acute myeloid leukemia."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-147030","json":"https://secwatch.observer/filing/0001193125-24-147030.json","markdown":"https://secwatch.observer/filing/0001193125-24-147030.md","text":"https://secwatch.observer/filing/0001193125-24-147030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000119312524147030/0001193125-24-147030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000119312524147030/d842527d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T08:39:19.942206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}